/
Our Business Overview Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor ( MCR ) system. Our product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.
Revenue declined 100.0% YoY. The question is whether this is cyclical or a structural shift.
ROIC dropped from -2002.26% to -3658.14%, capital efficiency is deteriorating. Negative free cash flow of -$21M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$0.00
▼ -100.0% YoY
Net Income (TTM)
-$6M
▲ +41.8% YoY
Op. Margin
—
ROIC
-88.09%
▼ -1655.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$15M
▲ +32.4% YoY
Op. Cash Flow (TTM)
-$15M
▲ +32.3% YoY
Net Debt
-$10M
Net Cash Position
Cash & Equiv.
$10M
Continue Research